Although there is a marked heterogeneity between the reported outcomes in the identified studies, all of them reported superior ORR in the angioimmunoblastic T-cell lymphoma subtype suggesting that AITL may be particularly responsive to HDAC inhibitor therapy compared to other peripheral T-cell lymphoma subtypes. This evidence concerns the gene HDAC9 and T-cell non-Hodgkin lymphoma.